Journal of Clinical & Experimental Dermatology Research
Open Access

Rosário Alves

Publications

• Rapid Communication
  Effectiveness of Aprepitant in Patients with Refractory Pruritus Secondary to Sézary Syndrome
  Author(s): Lolanda Conde Fernandes, Tiago Torres, Manuela Selores, Rosário Alves and Margarida Lima Lolanda Conde Fernandes, Tiago Torres, Manuela Selores, Rosário Alves and Margarida Lima
  
  Background: In advanced stages, patients with Sézary Syndrome (SS) commonly report an ill-defined, severe and diffuse pruritus. Recently, it has been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) antagonist, may have an important role in relief of refractory pruritus in patients with SS. Material and methods: A prospective study which included four patients with SS, in whom pruritus is the main symptom, was performed. Our purpose was to assess efficacy of Aprepitant for treatment of refractory pruritus, secondary to SS. Patients were treated with Aprepitant 80 mg/d during 10 days and then the dosage was reduced to alternate days. The length of treatment ranged between 4 and 23 weeks. Improvement was assessed by the Dermatology Life Quality Index (DLQI) questionnaire, which ranges from 0 to 30, with high scores indicating .. View More»
  DOI: 10.4172/2155-9554.1000149

  Abstract PDF

Relevant Topics